Add BrightSurf on Google Email

New neuroendocrine markers PITX2, PHOX2B, and HAND2 do not offer diagnostic utility in fine-needle aspiration biopsies of primary and secondary medullary thyroid carcinomas

A retrospective study found that PITX2, PHOX2B, and HAND2 do not offer diagnostic utility in fine-needle aspiration biopsies of primary and secondary medullary thyroid carcinomas. The markers were expressed in some samples but did not improve diagnosis accuracy.

SourceXia & He Publishing Inc.·JournalJournal of Clinical and Translational Pathology·DateJun 29, 2026

ESE and ESPE launch joint transition of care guidance to improve outcomes for young people moving from child to adult endocrine care

The ESE and ESPE have launched a landmark Joint Clinical Practice Guidance to support structured and effective transition of young people with endocrine conditions. The Guidance provides practical, evidence-based recommendations to ensure continuity, safety and quality of care during this critical phase in a patient's life.

Seeing thyroid cancer in a new light: when AI meets label-free imaging in the operating room

Researchers combined Dynamic Optical Contrast Imaging (DOCI) with machine learning to identify thyroid cancer during surgery. The AI analysis framework accurately classified samples across three categories and generated tumor probability maps for precise location identification.

SourceSPIE--International Society for Optics and Photonics·JournalBiophotonics Discovery·TypeObservational study·DateJan 6, 2026

Next-generation targeted alpha therapy using astatine shows promise in thyroid cancer resistant to conventional treatment

A first-in-human study found that a single dose of the alpha-emitting radionuclide <sup> 211 </sup> At was both well-tolerated and effective in achieving disease control without molecularly targeted drugs. The therapy has potential to reduce treatment burden and broaden access to effective care for patients with refractory disease.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateDec 5, 2025

New ATA management guidelines for adult patients with differentiated thyroid cancer

The American Thyroid Association has released new guidelines for managing adult patients with differentiated thyroid cancer, emphasizing evidence-based recommendations for diagnosis, treatment, and monitoring. The guidelines highlight the importance of patient-reported outcomes and areas for further research.

SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalThyroid·TypeSystematic review·DateAug 26, 2025

Cancer screenings continue years after guidelines change to limit unnecessary tests, study finds

Researchers found that it took 13 years for cervical cancer screenings to halve among women over 65, and even longer for prostate cancer screenings to decrease significantly. The study emphasizes the need for more effective tracking mechanisms to identify and reduce inappropriate screening practices.

SourceUniversity of Florida·JournalBMJ Quality & Safety·TypeData/statistical analysis·DateJun 9, 2025

Scientists develop super strong antibodies for new cancer treatment

Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.

SourceUniversity of Southampton·JournalNature Communications·TypeExperimental study·DateMay 1, 2025

Radioiodine therapy improves relative survival rates of differentiated thyroid cancer patients

A new study finds that radioiodine therapy significantly increases relative survival rates in differentiated thyroid cancer patients, with benefits observed across low-, intermediate-, and high-risk subgroups. The treatment reduces recurrence rates and improves long-term survival in high-risk groups, while also showing promise for low-...

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateApr 25, 2025

IGTP-led study identifies an epigenetic signature with prognostic value in metastatic thyroid cancer

A study led by IGTP identifies an epigenetic signature of 156 altered CpG sites in primary tumours that can help stratify patients according to their risk of developing distant metastases. The findings contribute to a better understanding of the disease and open new avenues for patient stratification and personalised treatment strategies.

SourceGermans Trias i Pujol Research Institute·JournalThyroid·TypeData/statistical analysis·DateApr 25, 2025

HKUMed develops world’s first AI model for thyroid cancer diagnosis, with over 90% accuracy and reduced consultation preparation time

The HKUMed AI model achieves over 90% accuracy in classifying both thyroid cancer stage and risk category. The model reduces pre-consultation preparation time for frontline clinicians by approximately 50%, making it a significant advancement in precision management of the disease.

SourceThe University of Hong Kong·Journalnpj Digital Medicine·TypeExperimental study·DateApr 24, 2025

Early-life exposure to air and light pollution linked to increased risk of pediatric thyroid cancer

A new study by Yale University researchers suggests that early-life exposure to small particle air pollution and outdoor artificial light at night may increase the risk of pediatric thyroid cancer. The study found a significant association between these exposures and increased risk of papillary thyroid cancer in children and young adults.

SourceYale University·JournalEnvironmental Health Perspectives·DateApr 17, 2025

UTHealth Houston research: Children born to young men with cancer have slight increases in preterm birth, low-birth-weight children, but not birth defects

According to UTHealth Houston research, adolescent and young adult men with cancer have a slightly elevated risk of having preterm birth and children with low birth weight. However, the likelihood of live birth was highest for fathers who had thyroid cancer and lowest for those with gastrointestinal cancer.

SourceUniversity of Texas Health Science Center at Houston·JournalJNCI Journal of the National Cancer Institute·TypeData/statistical analysis·DateJan 16, 2025

Combining targeted therapy and immunotherapy improves overall survival in patients with anaplastic thyroid cancer

Researchers at the University of Texas MD Anderson Cancer Center demonstrated that combining anti-PD-L1 immunotherapy with mutation-directed targeted therapy extended overall survival in patients with anaplastic thyroid carcinoma. The median OS across all cohorts was 19 months, compared to five months for historical data.

Chinese Medical Journal study reveals key insights on the global burden of thyroid cancer in 2022

A study published in the Chinese Medical Journal projects a significant rise in global thyroid cancer burden, with 821,214 new cases and 47,507 related deaths reported worldwide in 2022. The incidence is expected to increase by 44.1% from 2019 to 2030, with women experiencing higher rates than men.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·TypeObservational study·DateOct 16, 2024

Scientists discover how the body's killer cells attack cancer

Researchers have found that natural killer cells instinctively recognize and attack the XPO1 protein, which drives cancer growth. By targeting this protein, scientists may be able to activate more killer cells to destroy cancer cells. The study suggests that this approach could lead to personalized cancer treatment with less side effects.

SourceUniversity of Southampton·JournalScience Advances·TypeRandomized controlled/clinical trial·DateAug 28, 2024

Subclinical hypothyroidism during first half of pregnancy is associated with hypothyroidism 1-5 years after delivery

A new study found that subclinical hypothyroidism diagnosed before 21 weeks of pregnancy is associated with higher rates of overt hypothyroidism or thyroid replacement therapy within 5 years after delivery. Women with high TSH values and elevated TPO antibodies were at increased risk.

SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalThyroid·TypeObservational study·DateAug 2, 2024

Mayo Clinic marks medical milestone with world’s first known successful total larynx transplant performed in a patient with an active cancer as part of a clinical trial

Mayo Clinic's surgical team successfully performed the rare procedure, which included multiple organs, on a Massachusetts man with a rare form of laryngeal cancer. The landmark surgery, conducted as part of a clinical trial, marks a significant step towards making larynx transplantation available to a wider population.

SourceMayo Clinic·JournalMayo Clinic Proceedings·DateJul 9, 2024

Families of men with fertility problems show distinct patterns of increased risk for several types of cancer

Men with low sperm count or none have a higher risk of developing cancer, including at younger ages, compared to fertile men. Families of azoospermic men have a significantly increased risk of five cancers, while families of oligozoospermic men have a higher risk of colon, bone and joint, and testicular cancers.

SourceEuropean Society of Human Reproduction and Embryology·JournalHuman Reproduction·TypeObservational study·DateFeb 21, 2024

NTRK gene fusion in papillary thyroid cancer: A clinicogenomic biobank and record linkage study from Finland

Researchers identified NTRK gene fusion in 1.5% of Finnish papillary thyroid cancer patients, with notable co-occurring genetic alterations and favorable treatment outcomes. The study highlights the potential for biobank samples linked to electronic health records to describe patient characteristics and outcomes.

SourceImpact Journals LLC·JournalOncotarget·TypeObservational study·DateFeb 19, 2024

Novel PET tracer enhances lesion detection in medullary thyroid cancer, offers potential for targeted therapy

A novel PET imaging agent has been found to effectively identify medullary thyroid cancer (MTC) in preclinical and clinical studies. The compound demonstrates favorable tumor uptake and improved activity clearance from off-target tissues, potentially enhancing lesion detection and enabling targeted MTC radioligand therapy.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateJan 11, 2024

Certain per- and polyfluoroalkyl “forever chemicals” identified as potential risk factor for thyroid cancer

A recent study published in eBioMedicine found an association between certain per- and polyfluoroalkyl substances (PFAS) and an increased risk of thyroid cancer. The researchers investigated plasma PFAS levels in thyroid cancer patients and non-cancer controls, finding a significant positive association with exposure to n-PFOS.

Offspring of teen, young adult women with cancer history more likely to have birth defects

A recent study by UTHealth Houston found that the offspring of adolescent and young adult women with a history of cancer face a higher risk of birth defects. The study examined 6,882 offspring ages 12 months and younger and found an increased risk of specific types of defects in the offspring of women with a history of cancer.

SourceUniversity of Texas Health Science Center at Houston·JournalCancer Epidemiology Biomarkers & Prevention·DateOct 6, 2023

Adding immune modulator to targeted therapy does not improve survival in difficult-to-treat thyroid cancer

A phase II clinical trial shows that adding an immunomodulatory agent to treatment with a targeted tyrosine kinase inhibitor did not improve disease-free survival for patients with advanced differentiated thyroid cancer. The study found cediranib to be an active agent, but combining it with lenalidomide didn't yield better results.

SourceUniversity of Chicago Medical Center·JournalAnnals of Oncology·DateSep 1, 2023

A new generic treatment for multiple types of cancer

Researchers have developed a new technique to generically treat several kinds of cancer, showing tumors grew almost three times less and survival rates reached 100% after just one injection. The method targets cancer cells with alpha radiation, sparing healthy tissue.

SourceRIKEN·JournalChemical Science·DateJun 27, 2023